ライフサイエンスコーパス: prednisone

1 ophosphamide, vincristine, procarbazine, and prednisone).

2 graft failure in the absence of maintenance prednisone.

3 lophosphamide, doxorubicin, vincristine, and prednisone.

4 ore/Wegener's Granulomatosis (BVAS/WG)=0 off prednisone.

5 in 292 [38%] patients receiving placebo plus prednisone.

6 cyclophosphamide, doxorubicin, vincristine, prednisone.

7 ldenone, or its conjugates, prednisolone and prednisone.

8 herapy that included either dexamethasone or prednisone.

9 ared with historical controls on maintenance prednisone.

10 months of starting abiraterone acetate plus prednisone.

11 of patients in 2000-2004 received melphalan-prednisone.

12 lophosphamide, doxorubicin, vincristine, and prednisone.

13 stirsen and 512 were allocated docetaxel and prednisone.

14 rly subgroups and among pairs receiving oral prednisone.

15 r D75 intravenously every 3 weeks plus daily prednisone.

16 y), or avacopan (30 mg, twice daily) without prednisone.

17 g/m(2) intravenously every 21 days plus oral prednisone 10 mg daily) with or without custirsen (640 m

18 umab-related adverse events to grade 0-1 and prednisone 10 mg/day or less for at least 2 weeks, an Ea

19 Patients were given prednisone (10 to 40 mg/d) when the study began and were

20 ] all on day 1 of the 21-day cycle; and oral prednisone 100 mg/m(2) each day on days 1-5 of the cycle

21 recommendations, initial therapy for PMR is prednisone, 12.5 to 25 mg/day or equivalent, and 40 to 6

22 copan (30 mg, twice daily) plus reduced-dose prednisone (20 mg daily), or avacopan (30 mg, twice dail

23 th continuous cyclophosphamide (50 mg/d) and prednisone (20 mg/d).

24 ed to receive dexamethasone (14 days) versus prednisone (28 days) during induction and high-dose meth

25 At month 6, 24 (51%) of 47 patients assigned prednisone, 32 (70%) of 46 allocated prednisone plus cic

26 Fifty severe asthmatics received prednisone 40 mg/d for 2 weeks and maintenance therapy w

27 [1.4 mg/m(2), up to 2 mg] all on day 1, and prednisone [40 mg/m(2)] daily for 5 days), administered

28 lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001).

29 :1 schedule to receive orteronel 400 mg plus prednisone 5 mg twice daily or placebo plus prednisone 5

30 prednisone 5 mg twice daily or placebo plus prednisone 5 mg twice daily, stratified by region (Europ

31 ratio to cabozantinib 60 mg once per day or prednisone 5 mg twice per day.

32 to receive a tapering 15-day course of oral prednisone (5 days each of 60 mg, 40 mg, and 20 mg; tota

33 receive docetaxel (75 mg/m(2)) on day 1 and prednisone (5 mg twice daily) on days 1-21 and either le

34 e acetate, 1000 mg, once daily by mouth with prednisone, 5 mg, by mouth twice daily.

35 biraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily was administered to all pa

36 ailure was 16.7 months in patients allocated prednisone, 53.3 months in those assigned prednisone plu

37 lophosphamide, doxorubicin, vincristine, and prednisone (58%), with local radiation therapy added in

38 efore plus oral melphalan 9 mg/m(2) and oral prednisone 60 mg/m(2), days 1 to 4, every other cycle),

39 either dexamethasone (10 mg/m(2) per day) or prednisone (60 mg/m(2) per day) for 3 weeks plus taperin

40 of rituximab, 1000 mg, in 1 patient and oral prednisone, 60 mg/d, in the other patient, resulted in i

41 ents were higher with cabozantinib than with prednisone (71% v 56% and 33% v 12%, respectively).

42 sponse [PGR]) (dexamethasone, 91.4 +/- 2.4%; prednisone, 82.6 +/- 3.2%; P = .036).

43 total cohort (dexamethasone, 90.3 +/- 0.7%; prednisone, 90.5 +/- 0.7%).

44 ituximab, cyclophosphamide, vincristine, and prednisone (adjusted HR, 0.94; 95% CI, 0.62-1.42).

45 ycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP

46 G APML3 (single arm of ATRA + idarubicin +/- prednisone), ALLG APML4 (single arm of ATRA + idarubicin

47 over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in t

48 ate prolonged overall survival compared with prednisone alone by a margin that was both clinically an

49 dnisone discontinuation was 35.8 months with prednisone alone compared with 29.4-29.7 months in the c

50 e randomly assigned participants to continue prednisone alone for 1 month (control) or to add a singl

51 f abiraterone acetate plus prednisone versus prednisone alone for patients with metastatic CRPC.

52 roup (n=501) compared with the docetaxel and prednisone alone group (n=499) were neutropenia (grade 3

53 roup and 24 (5%) deaths in the docetaxel and prednisone alone group.

54 139 patients via a computer-based system to prednisone alone or in combination with either ciclospor

55 238 (44%) patients initially receiving prednisone alone subsequently received abiraterone aceta

56 randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either met

57 12, 2010, 47 patients were randomly assigned prednisone alone, 46 were allocated prednisone plus cicl

58 , and custirsen combination or docetaxel and prednisone alone.

59 and 181 (36%) of 499 receiving docetaxel and prednisone alone.

60 orin or methotrexate was more effective than prednisone alone.

61 al comparing thymectomy plus prednisone with prednisone alone.

62 alternate-day prednisone with alternate-day prednisone alone.

63 y assigned to abiraterone plus prednisone or prednisone alone.

64 red with patients treated with docetaxel and prednisone alone.

65 The abiraterone acetate plus prednisone and prednisone-alone groups demonstrated a significant survi

66 % CI 28.6-not estimable) with orteronel plus prednisone and 29.5 months (27.0-not estimable) with pla

67 lophosphamide, doxorubicin, vincristine, and prednisone and 6 cyclophosphamide, doxorubicin, vincrist

68 onths (95% CI 13.1-14.9) with orteronel plus prednisone and 8.7 months (8.3-10.9) with placebo plus p

69 events of grade 3 or worse in the docetaxel, prednisone and custirsen group (n=501) compared with the

70 Combined treatment with prednisone and either ciclosporin or methotrexate was mo

71 358 [46%] patients receiving orteronel plus prednisone and in 292 [38%] patients receiving placebo p

72 d Drug Administration-approved therapy) from prednisone and mitoxantrone and was predictive of overal

73 clophosphamide/methylprednisolone infusions, prednisone and mycophenolate.

74 The abiraterone acetate plus prednisone and prednisone-alone groups demonstrated a si

75 Dosing of prednisone and safety were also assessed.

76 SG patients were subjected to treatment with prednisone and/or glucocorticoid-sparing agents.

77 lophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mit

78 lophosphamide, vincristine, doxorubicin, and prednisone) and the rituximab (R)-CHOP eras.

79 ophosphamide, vincristine, procarbazine, and prednisone), and six cycles of COPP-EBV-CAD (cyclophosph

80 ituximab, cyclophosphamide, vincristine, and prednisone, and a clinical trial validation cohort compr

81 nisone, and lenalidomide (DPL) or docetaxel, prednisone, and a placebo (DP).

82 43%) of 501 patients treated with docetaxel, prednisone, and custirsen and 181 (36%) of 499 receiving

83 trial, of whom 510 were assigned docetaxel, prednisone, and custirsen and 512 were allocated docetax

84 igned 1:1 centrally to either the docetaxel, prednisone, and custirsen combination or docetaxel and p

85 ibutable to 23 (5%) deaths in the docetaxel, prednisone, and custirsen group and 24 (5%) deaths in th

86 Patients assigned docetaxel, prednisone, and custirsen received weekly doses of custi

87 .4 months [95% CI 20.9-24.8] with docetaxel, prednisone, and custirsen vs 22.0 months [19.5-24.0] wit

88 ive rituximab, cyclophosphamide, adriamycin, prednisone, and either vincristine (R-CHOP) or bortezomi

89 059 patients with mCRPC receiving docetaxel, prednisone, and lenalidomide (DPL) or docetaxel, prednis

90 one, and thalidomide (MPT-T) with melphalan, prednisone, and lenalidomide (mPR-R) in patients with un

91 Melphalan, prednisone, and lenalidomide, followed by lenalidomide m

92 king immunosuppression with oral tacrolimus, prednisone, and mycophenolate mofetil, which has continu

93 protocol included thymoglobulin, tacrolimus, prednisone, and mycophenolate mofetil.

94 t recipients receiving reduced TAC exposure, prednisone, and mycophenolate, randomized at 3 months to

95 trial, 526 patients treated with docetaxel, prednisone, and placebo in the MAINSAIL trial, 598 patie

96 L (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng

97 The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard

98 logy Group [ECOG] E1A06) compared melphalan, prednisone, and thalidomide (MPT-T) with melphalan, pred

99 Glucocorticoid steroids such as prednisone are prescribed for chronic muscle conditions

100 Glucocorticoid steroids, like prednisone, are known to delay loss of ambulation in pat

101 bsequently received abiraterone acetate plus prednisone as crossover per protocol (93 patients) or as

102 ophosphamide, vincristine, procarbazine, and prednisone at baseline over ABVD was not observed.

103 Index (CDAI) of 150-450 depending on dose of prednisone at baseline, and no previous use of immunomod

104 lophosphamide, doxorubicin, vincristine, and prednisone) at the British Columbia Cancer Agency.

105 ic pulmonary fibrosis in a clinical trial of prednisone, azathioprine, and N-acetylcysteine underwent

106 ophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) and INRT (superiority design).

107 All patients received a mandatory prednisone burst followed by tapering of prednisone over

108 th patients in VISUAL-1 receiving an initial prednisone burst.

109 s (block size 8) to receive cabazitaxel plus prednisone (cabazitaxel 25 mg/m(2) intravenously every 2

110 rm of ATRA + idarubicin + arsenic trioxide + prednisone), CALGB C9710 (single arm of ATRA + cytarabin

111 lophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.

112 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP) +/- rituximab were used.

113 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the mana

114 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radio

115 e, hydroxydaunorubicin, vincristine sulfate, prednisone (CHOP) or rituximab-CHOP-like chemotherapy wi

116 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatme

117 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP), nowadays represent the standard first

118 lophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or eight cycles of cyclophosphamide, v

119 ombination of carfilzomib with melphalan and prednisone (CMP) in patients aged >65 years with newly d

120 y distress syndrome (odds ratio for 30 mg of prednisone compared with 5 mg 0.53; 95% CI, 0.32-0.86).

121 lophosphamide, doxorubicin, vincristine, and prednisone compared with rituximab, cyclophosphamide, vi

122 tion with cyclophosphamide, vincristine, and prednisone (CVP) in patients with newly diagnosed advanc

123 cycles of cyclophosphamide, vincristine, and prednisone [CVP]), every 3 weeks during induction, then

124 with three cycles of doxorubicin/vincristine/prednisone/cyclophosphamide (AV-PC).

125 the mitoxantrone data were compared with the prednisone data (41, 39, and 41 patients in the three mi

126 lophosphamide, doxorubicin, vincristine, and prednisone delivered in a 21-day cycle (R-CHOP-21) for s

127 autoimmune event occurring in the airways of prednisone-dependent asthmatic patients with increased e

128 Median time to prednisone discontinuation was 35.8 months with predniso

129 Equation (GEE) model, each 10 mg increase in prednisone dose is associated with a 1.5- and 2.6-fold i

130 The cumulative median prednisone dose over the 52-week period was 1862 mg in e

131 eks and were taking a stable prednisolone or prednisone dose to receive 300 mg of mepolizumab or plac

132 s and were maintained in remission with high prednisone doses (>/=0.7 mg/kg per day).

133 However, daily prednisone dosing also correlated with increased muscle

134 at in murine models of LGMD 2B and 2C, daily prednisone dosing reduced muscle damage and fibroinflamm

135 ophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for six cycles.

136 hosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, v

137 with peripheral neuropathy, glucocorticoid (prednisone equivalent) dose >/=8000 mg/m(2) with hand we

138 00; 95% CI, 0.99-1.01, per 10 mg increase in prednisone equivalent).

139 ose of 50 mg (interquartile range, 25-75 mg) prednisone equivalent.

140 patients receiving oral corticosteroids, in prednisone equivalents, was 10 mg (interquartile range,

141 lymphocytic leukemia and being treated with prednisone, fludarabine, cyclophosphamide, and rituximab

142 cyclophosphamide, doxorubicin, vincristine, prednisone) followed by 3 cycles of ICE (ifosfamide, car

143 significantly worse than with docetaxel and prednisone for chemotherapy-naive men with metastatic, c

144 lophosphamide, doxorubicin, vincristine, and prednisone) for DLBCL.

145 sing 476 patients treated with docetaxel and prednisone from the ASCENT2 trial, 526 patients treated

146 lophosphamide, doxorubicin, vincristine, and prednisone given every 14 days (R-CHOP-14) under standar

147 nd good response to the prednisone prephase (prednisone good-response [PGR]) (dexamethasone, 91.4 +/-

148 2013 plus cyclophosphamide, vincristine, and prednisone (GP2013-CVP) with rituximab-CVP (R-CVP) in pa

149 21 (81.0%) patients in the avacopan without prednisone group (difference from control 11.0%; two-sid

150 ) patients in the avacopan plus reduced-dose prednisone group (difference from control 16.4%; two-sid

151 n the dexamethasone and 15.6 +/- 0.8% in the prednisone group (P < .0001), showing the largest effect

152 k mean ODI scores were 51.2 and 32.2 for the prednisone group and 51.1 and 37.5 for the placebo group

153 The prednisone group showed an adjusted mean 3.3-point (95%

154 [17%] of 784 patients in the orteronel plus prednisone group vs 14 [2%] of 770 patients in the place

155 14 [2%] of 770 patients in the placebo plus prednisone group), increased amylase (77 [10%] vs nine [

156 irsen group and n=318 in the cabazitaxel and prednisone group).

157 ) patients in the avacopan plus reduced-dose prednisone group, and 21 of 22 (96%) patients in the ava

158 nt related, versus 17 in the cabazitaxel and prednisone group, eight of which were deemed to be treat

159 of 22 (96%) patients in the avacopan without prednisone group.

160 terior synechiae (aHR, 1.81); current use of prednisone >7.5 mg/day (aHR, 1.86); periocular corticost

161 and 8.7 months (8.3-10.9) with placebo plus prednisone (hazard ratio [HR] 0.71, 95% CI 0.63-0.80; p<

162 ths with orteronel-prednisone versus placebo-prednisone (hazard ratio [HR], 0.886; 95% CI, 0.739 to 1

163 months with cabozantinib and 9.8 months with prednisone (hazard ratio, 0.90; 95% CI, 0.76 to 1.06; st

164 s 22.0 months [19.5-24.0] with docetaxel and prednisone; hazard ratio [HR] 0.93, 95% CI 0.79-1.10; p=

165 onths (27.0-not estimable) with placebo plus prednisone (HR 0.92, 95% CI 0.79-1.08; p=0.31).

166 roperties, in combination with docetaxel and prednisone in chemotherapy-naive patients with metastati

167 d not significantly improve OS compared with prednisone in heavily treated patients with mCRPC and pr

168 ion-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-res

169 d phase III trial compared cabozantinib with prednisone in patients with mCRPC.

170 ine the efficacy of abiraterone acetate with prednisone in these high-risk patients with a suboptimal

171 ophosphamide, vincristine, procarbazine, and prednisone) in the German Hodgkin Study Group HD12 and H

172 were generally more frequent with orteronel-prednisone, including nausea (42% v 26%), vomiting (36%

173 ustirsen in combination with cabazitaxel and prednisone increases overall survival in patients with m

174 rPFS and a higher PSA50 rate with orteronel-prednisone indicate antitumor activity.

175 on (</=2 years or >2 years) after 8 weeks of prednisone induction therapy, or earlier if they had act

176 reduced following cGVHD therapies including prednisone, interleukin-2, or extracorporeal photophores

177 isone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus low-d

178 eligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-predni

179 (cyclophosphamide, doxorubicin, vincristine, prednisone)-like chemotherapy, who were enrolled in stud

180 ature eosinophils, sputum EoP numbers or the prednisone maintenance dose.

181 oglobulin-rituximab induction and tacrolimus-prednisone maintenance.

182 Improved rPFS was observed with orteronel-prednisone (median, 8.3 v 5.7 months; HR, 0.760; 95% CI,

183 s were compared between study interventions (prednisone, mitoxantrone, and docetaxel) and off-treatme

184 h ponatinib 45 mg daily with vincristine and prednisone monthly for 2 years followed by ponatinib ind

185 ndomly assigned to cabozantinib (n = 682) or prednisone (n = 346).

186 onel plus prednisone (n=781) or placebo plus prednisone (n=779).

187 ly assigned to receive either orteronel plus prednisone (n=781) or placebo plus prednisone (n=779).

188 bitor), anakinra (IL-1 receptor antagonist), prednisone (NFkappaB translocation inhibitor), or ibupro

189 had an average daily dose of prednisolone or prednisone of 4.0 mg or less per day during weeks 48 thr

190 se oral cyclophosphamide to lenalidomide and prednisone offers a new therapeutic perspective for mult

191 custirsen in combination with docetaxel and prednisone on overall survival in patients with metastat

192 ssing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and

193 patients in the thymectomy group than in the prednisone-only group required immunosuppression with az

194 ive therapies with steroid molecules such as prednisone or deflazacort thought to act through their i

195 e (C-MTX) during interim maintenance (IM) or prednisone or dexamethasone during induction.

196 f ipilimumab therapy, most commonly low-dose prednisone or hydroxychloroquine.

197 lestones by 2.1-2.7 years in comparison with prednisone or prednisolone (log-rank p<0.012).

198 trial, 598 patients treated with docetaxel, prednisone or prednisolone, and placebo in the VENICE tr

199 s were randomly assigned to abiraterone plus prednisone or prednisone alone.

200 lophosphamide, doxorubicin, vincristine, and prednisone or rituximab, etoposide, prednisone, vincrist

201 hma maintained on high-dose corticosteroids, prednisone, or both.

202 etaxel 75 mg/m(2) intravenously with 5 mg of prednisone orally twice daily.

203 d the time-weighted average required dose of prednisone over a 3-year period.

204 ory prednisone burst followed by tapering of prednisone over the course of 15 weeks.

205 0.9% for dexamethasone and 80.8 +/- 0.9% for prednisone (P = .024).

206 (1.95 fold [95% CI 1.20-3.15] increase with prednisone; p=0.009).

207 y of the mTOR-inhibitor sirolimus (SRL) plus prednisone (PDN) in patients with ECD.

208 significantly increased in patients assigned prednisone plus ciclosporin and prednisone plus methotre

209 ntly greater proportion of patients assigned prednisone plus ciclosporin had adverse events, affectin

210 ssigned prednisone, 32 (70%) of 46 allocated prednisone plus ciclosporin, and 33 (72%) of 46 administ

211 assigned prednisone alone, 46 were allocated prednisone plus ciclosporin, and 46 were randomised pred

212 ed prednisone, 53.3 months in those assigned prednisone plus ciclosporin, but was not observable in p

213 domly assigned (n=317 in the cabazitaxel and prednisone plus custirsen group and n=318 in the cabazit

214 30 days of treatment in the cabazitaxel and prednisone plus custirsen group, seven of which were dee

215 and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in ch

216 was not observable in patients randomised to prednisone plus methotrexate (1.95 fold [95% CI 1.20-3.1

217 ciclosporin, and 33 (72%) of 46 administered prednisone plus methotrexate achieved a juvenile dermato

218 mission was 41.9 months in patients assigned prednisone plus methotrexate but was not observable in t

219 d-sparing effect favoured the combination of prednisone plus methotrexate.

220 nts assigned prednisone plus ciclosporin and prednisone plus methotrexate.

221 one plus ciclosporin, and 46 were randomised prednisone plus methotrexate.

222 ps (2.45 fold [95% CI 1.2-5.0] increase with prednisone plus methotrexate; p=0.012).

223 lophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year

224 These patients, classified as prednisone poor responders (PPR), have poorer outcome th

225 nts with T-cell ALL and good response to the prednisone prephase (prednisone good-response [PGR]) (de

226 After a 7-day prednisone prephase, 3720 patients enrolled on trial Ass

227 Conversely, intermittent dosing of prednisone, provided once weekly, enhanced muscle repair

228 cin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP) or rituximab, cyclophosphamide, dox

229 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at the British Columbia Cancer Agenc

230 mab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) chemotherapy showed a rapid clearanc

231 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and

232 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the RICOVER-60 trial.

233 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated

234 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and

235 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like therapy.

236 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment failure.

237 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were assembled on tissue microarrays

238 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), patients who fail R-CHOP have a dis

239 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-14 (eight cycles) with rituximab plu

240 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

241 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

242 cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP14) induction and a positron emission

243 been reported after rapid discontinuation of prednisone (RDP) in kidney transplant recipients.

244 Cabazitaxel and prednisone remains the standard of care for patients wit

245 ith continuous low-dose cyclophosphamide and prednisone (REP) had remarkable activity in heavily pret

246 l symptoms, enzalutamide or abiraterone plus prednisone should be offered after discussion with patie

247 of tocilizumab as additional treatment with prednisone showed a 2- to 4-fold increase in remission r

248 Abiraterone acetate plus prednisone significantly improved radiographic progressi

249 r relapsing vasculitis received placebo plus prednisone starting at 60 mg daily (control group), avac

250 tegy 2), or initial combination therapy with prednisone (strategy 3) or with infliximab (strategy 4),

251 the placebo group that underwent the 52-week prednisone taper (P<0.001 for the comparisons of either

252 the placebo group that underwent the 26-week prednisone taper and 18% of those in the placebo group t

253 kly dose 40 mg) or placebo, with a mandatory prednisone taper from week 2.

254 prednisone taper, or placebo combined with a prednisone taper over a period of either 26 weeks or 52

255 or every other week, combined with a 26-week prednisone taper was superior to either 26-week or 52-we

256 or every other week, combined with a 26-week prednisone taper, or placebo combined with a prednisone

257 the placebo group that underwent the 26-week prednisone taper.

258 the placebo group that underwent the 52-week prednisone taper.

259 er was superior to either 26-week or 52-week prednisone tapering plus placebo with regard to sustaine

260 All patients underwent prednisone tapering, with patients in VISUAL-1 receiving

261 vir, intravitreal dexamethasone and systemic prednisone, the change in vision in OD improved from lig

262 ansplant recipients receiving tacrolimus and prednisone, the use of EVR was associated with higher in

263 enatal intravenous immunoglobulin (IVIG) +/- prednisone therapy demonstrated a significant and modera

264 solone followed by a tapering course of oral prednisone therapy.

265 lophosphamide, doxorubicin, vincristine, and prednisone); this new combination is known as R2CHOP.

266 The prednisone-treated group showed an adjusted mean 6.4-poi

267 e the molecular differences and effects from prednisone treatment among IgG4-related disease with sal

268 eitis, or panuveitis despite having received prednisone treatment for 2 or more weeks.

269 Prednisone treatment led to increased neutrophil, but de

270 elated AEs among placebo patients during the prednisone treatment period in VISUAL-1 was statisticall

271 Prednisone treatment selectively modulates Treg, eosinop

272 rcolemma integrity was greatly reduced after prednisone treatment suggesting a role for this molecule

273 the addition of custirsen to cabazitaxel and prednisone treatment.

274 2 participants and resolved with short-term prednisone treatment.

275 to receive either 400 mg orteronel plus 5 mg prednisone twice daily or placebo plus 5 mg prednisone t

276 prednisone twice daily or placebo plus 5 mg prednisone twice daily.

277 /g, creatinine level greater than 1.2 mg/dL, prednisone use greater than 20 mg/d, and multifetal preg

278 ts compared with baseline or CDAI >/=200, or prednisone use in the previous week).

279 C-reactive protein >/=5mg/L, CDAI >/=150, or prednisone use in the previous week; clinical management

280 7.0 months versus 15.2 months with orteronel-prednisone versus placebo-prednisone (hazard ratio [HR],

281 el in this trial of abiraterone acetate plus prednisone versus prednisone alone for patients with met

282 ine, and prednisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubic

283 al report that bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexameth

284 Bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexameth

285 0 mg, days 1 to 21), or bortezomib-melphalan-prednisone (VMP; n = 167; bortezomib as before plus oral

286 ion of custirsen to first-line docetaxel and prednisone was reasonably well tolerated, but overall su

287 combination of lenalidomide, docetaxel, and prednisone was significantly worse than with docetaxel a

288 Prednisone was used concomitantly in 4 (57%) patients.

289 Melphalan and prednisone were administered orally on days 1 to 4; carf

290 lone, tacrolimus, mycophenolate mofetil, and prednisone were commenced.

291 ansplant recipients receiving tacrolimus and prednisone were randomized for 3 different regimens: rab

292 veitic uveitis controlled by 10-35 mg/day of prednisone were randomly assigned (1:1), via an interact

293 ient with active uveitis taking 60 mg/day of prednisone will experience, on average, an additional 10

294 nt with inactive uveitis taking 35 mg/day of prednisone will experience, on average, an additional 23

295 d transsternal thymectomy plus alternate-day prednisone with alternate-day prednisone alone.

296 , randomized trial comparing thymectomy plus prednisone with prednisone alone.

297 imab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide

298 lophosphamide, doxorubicin, vincristine, and prednisone, with or without melatonin.

299 us and randomly assigned to abiraterone plus prednisone without (arm A) or with veliparib (arm B).

300 lastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileuke